These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20089948)

  • 21. Hormone therapy and venous thromboembolism among postmenopausal women.
    Scarabin PY
    Front Horm Res; 2014; 43():21-32. PubMed ID: 24943295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exogenous hormones, the risk of venous thromboembolism, and activated protein C resistance.
    Mueck AO
    Menopause; 2010; 17(6):1099-103. PubMed ID: 20975607
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of menopausal hormones in the United States, 1992 through June, 2003.
    Wysowski DK; Governale LA
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):171-6. PubMed ID: 15386701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone therapy and thromboembolic disease.
    Battaglioli T; Martinelli I
    Curr Opin Hematol; 2007 Sep; 14(5):488-93. PubMed ID: 17934355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review.
    Fournier A
    Menopause Int; 2010 Mar; 16(1):23-32. PubMed ID: 20424283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism.
    Obstet Gynecol; 2013 Apr; 121(4):887-890. PubMed ID: 23635705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of hormone replacement therapy on antithrombin III and protein C levels in menopausal women.
    Lacroix KA; Bean C; Reilly R; Curran-Celentano J
    Clin Lab Sci; 1997; 10(3):145-8. PubMed ID: 10167774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Menopausal hormones and risk of ovarian cancer.
    Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A
    Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are some types of hormone therapy safer than others? Lessons from the Estrogen and Thromboembolism Risk study.
    Rexrode KM; Manson JE
    Circulation; 2007 Feb; 115(7):820-2. PubMed ID: 17309929
    [No Abstract]   [Full Text] [Related]  

  • 30. Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.
    Bouaziz E; Canonico M; Verstuyft C; Carcaillon L; Martin F; Scarabin PY; Guiochon-Mantel A;
    Maturitas; 2009 Oct; 64(2):136-8. PubMed ID: 19782484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic influence of hormone-replacement therapy on venous thromboembolism.
    Sumino H; Ichikawa S; Kumakura H; Takayama Y; Kurabayashi M
    Lancet; 2003 Oct; 362(9391):1242. PubMed ID: 14568759
    [No Abstract]   [Full Text] [Related]  

  • 32. Letter by Micheletti and Chevallier regarding article, "Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER Study".
    Micheletti MC; Chevallier T
    Circulation; 2007 Sep; 116(13):e362; author reply e363. PubMed ID: 17893283
    [No Abstract]   [Full Text] [Related]  

  • 33. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution.
    Chlebowski RT; Prentice RL
    J Natl Cancer Inst; 2008 Oct; 100(19):1341-3. PubMed ID: 18812547
    [No Abstract]   [Full Text] [Related]  

  • 34. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.
    Laliberté F; Dea K; Duh MS; Kahler KH; Rolli M; Lefebvre P
    Menopause; 2011 Oct; 18(10):1052-9. PubMed ID: 21775912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Menopausal hormone therapy and risk of venous thromboembolism: The story so far.
    Abdelhafez MMA; Ahmed KAM; Ahmed NAM; Ismail MH; Daud MNM; Eldiasty AME; Amri MFB; Jeffree MS; Masnah FK; Baharuddin DMP; Bolong MF; Hayati MF; Azizan NB; Sumpat D; Abdul Rahim SSS; Than WW; Ibrahim MY; Lo ZZ; Soe MZ
    Afr J Reprod Health; 2024 Mar; 28(3):122-129. PubMed ID: 38583076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormone replacement therapy and ovarian cancer risk--any news?
    Riman T
    Acta Obstet Gynecol Scand; 2007; 86(9):1032-4. PubMed ID: 17712640
    [No Abstract]   [Full Text] [Related]  

  • 37. IARC monographs program on carcinogenicity of combined hormonal contraceptives and menopausal therapy.
    Schneider HP; Mueck AO; Kuhl H
    Climacteric; 2005 Dec; 8(4):311-6. PubMed ID: 16390765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hormone therapy and risk of venous thromboembolism: new insights from the ESTHER study].
    Canonico M; Scarabin PY
    Med Sci (Paris); 2008 Mar; 24(3):228-31. PubMed ID: 18334161
    [No Abstract]   [Full Text] [Related]  

  • 39. [Postmenopausal hormone therapy--an update. Benefit versus risk--important to identify women with increased breast cancer risk].
    von Schoultz B
    Lakartidningen; 2009 Aug 19-25; 106(34):2041-2. PubMed ID: 19769143
    [No Abstract]   [Full Text] [Related]  

  • 40. Hormone therapy. An update on risks and benefits.
    Mayo Clin Womens Healthsource; 2009 Mar; Suppl():1-8. PubMed ID: 19405167
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.